UBS raised the firm’s price target on Molina Healthcare to $395 from $380 and keeps a Neutral rating on the shares. The price target increase reflects the more positive 2024 outlook and better line of sight into their embedded earnings for 2025, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MOH:
